deltatrials
Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06599658

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (CO2I2)

The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Conditions COVID 19 Immunocompromised Host Inflammatory Bowel Disease Influenza People Living With HIV Rheumatoid Arthritis (RA) Solid Organ Transplant Recipients Systemic Lupus Erthematosus
Interventions COVID-19 Vaccines at a 3-month interval COVID-19 Vaccines at a 6-month interval Inactivated influenza vaccine (IIV) at baseline Inactivated influenza vaccine at Month 1
Updated 4 times since 2024 Last updated: Mar 6, 2026 Started: Nov 20, 2024 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates COVID 19 and Immunocompromised Host and is currently actively recruiting participants. Centre hospitalier de l'Université de Montréal (CHUM) leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshotNot Yet Recruiting~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshotRecruiting~Sep 2025 – ~Mar 2026 · 6 months · monthly snapshotRecruiting~Mar 2026 – present · 4 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Mar 2026 [monthly]

    Recruiting PHASE2

  3. Dec 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Oct 2024 — Dec 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre hospitalier de l'Université de Montréal (CHUM)
  • McGill University Health Centre/Research Institute of the McGill University Health Centre
Data source: McGill University Health Centre/Research Institute of the McGill University Health Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations